Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Endocrine 1

Conditions

Small Cell Lung Carcinoma 2Carcinoma, Non-Small-Cell Lung 2Extensive Stage Small Cell Lung Cancer 1Carcinoma, Small Cell 1Carcinoma, Neuroendocrine 1

Interventions

atezolizumab 4Nivolumab 4Cisplatin 4Topotecan 2Radiosurgery 2Paclitaxel 2Ipilimumab 2Immunoglobulin G 2Etoposide 2Disulfides 2veliparib 1tocilizumab 1repotrectinib 1pralsetinib 1pembrolizumab 1niraparib 1iadademstat 1durvalumab 1dostarlimab 1cabozantinib 1budigalimab 1berzosertib 1belinostat 1Temozolomide 1Specimen Handling 1Radiotherapy 1Podophyllotoxin 1Platinum 1Magnetic Resonance Spectroscopy 1Irinotecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Neuroendocrine × Podophyllotoxin × Thoracic × Clear all
NCT01642251 2023-05-06

Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
156 enrolled 13 charts
EndocrineThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Neuroendocrine, Carcinoma, Small Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡